Pfizer Ends Testing of Obesity Pill, Danuglipron, After Possible Liver Injury

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on April 15, 2025.

By I. Edwards HealthDay Reporter

TUESDAY, April 15, 2025 — Pfizer has stopped developing a once-daily pill to treat obesity after a person in a clinical trial showed signs of a possible liver injury.

The company said the injury went away after the person stopped taking the drug, called danuglipron, The Associated Press reported.

The pill was in early testing to help determine the best dose, according to a Pfizer spokeswoman.

The company had planned to move the drug into late-stage trials, typically the final step before review by the U.S. Food and Drug Administration (FDA).

Pfizer will now stop all testing of danuglipron, including its use with other drugs for obesity treatment. However, the company said it still plans to work on other obesity treatments that are in earlier stages of research.

Obesity drugs have become a major focus for pharmaceutical companies. Injectable treatments like Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy have brought in billions in revenue. Zepbound earned nearly $5 billion in 2024 alone, The Associated Press reported.

But these drugs must be injected, which some folks don't want to do.

As a result, drugmakers have been racing to develop pill versions. Lilly expects to release new data this year on two oral obesity drugs it is studying.

While demand for these treatments is high, access has been an issue. Some patients face insurance issues or high out-of-pocket costs.

Even with recent price cuts, many of these medications still cost hundreds of dollars per month.

Pfizer had already stopped testing of a twice-daily version of danuglipron in late 2023 after more than half the people in a trial stopped taking it.

Sources

  • The Associated Press, April 14, 2025

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2025-04-16 06:00

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords